These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 1760902)

  • 1. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
    Marchetti P; Navalesi R
    Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
    Jennings PE
    Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a concentration-effect relationship for sulphonylureas?
    Melander A; Donnelly R; Rydberg T
    Clin Pharmacokinet; 1998 Mar; 34(3):181-8. PubMed ID: 9533980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antidiabetic medications in overdose.
    Spiller HA
    Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinically important effects of oral antidiabetic drug interactions].
    Drzewoski J; Kopff B
    Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antidiabetic agents. A guide to selection.
    Scheen AJ; Lefèbvre PJ
    Drugs; 1998 Feb; 55(2):225-36. PubMed ID: 9506242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
    van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
    BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
    Seshiah V; Shanker R; Madhavan R; Venkataraman S; Sundaram A; Seshasaianam C; Sankaran JR
    J Assoc Physicians India; 1992 Oct; 40(10):666-8. PubMed ID: 1307353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biguanides and NIDDM.
    Bailey CJ
    Diabetes Care; 1992 Jun; 15(6):755-72. PubMed ID: 1600835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.